Literature DB >> 26248239

Glucagonoma syndrome associated with necrolytic migratory erythema.

Florentino de Araújo Cardoso Filho1, Roney Gonçalves Fechine Feitosa2, Carolina Oliveira Costa Fechine3, Carlos Márcio Melo de Matos4, Amanda Linhares Cardoso5, Daniel Linhares Cardoso6.   

Abstract

INTRODUCTION: glucagonoma is a pancreatic neuroendocrine tumor derived from alpha-cells of the islets of Langerhans. It is marked by tumoral autonomous production of glucagon and characterized, among other symptoms, by necrolytic migratory erythema, an erythematous circinate lesion with areas of necrosis and sloughing. This is a rare disease with worldwide incidence estimated at 1 case per 20 million people. CASE REPORT: we report a case of glucagonoma associated necrolytic migratory erythema in a male patient, 56 years, with signs of skin lesions mainly on his legs and groin, hyperglycemia and weight loss. Biopsies of the skin lesions were performed and imaging of the abdomen showed a mass of 10 x 9 cm, at the pancreatic region. The patient was subjected to body-caudal pancreatectomy and splenectomy with autotransplant of the spleen in the greater omentum. The histopathologic report indicated a tumor in the pancreatic alpha cells. Immunohistochemistry showed expression of glucagon and chromogranin A in most tumor cells, consistent with the diagnosis of glucagonoma. The patient presented 3 years of outpatient follow-up with no complications.
CONCLUSION: the necrolytic migratory erythema is important for the clinical recognition of glucagonoma, and its early diagnosis is essential for a successful curative therapy.

Entities:  

Mesh:

Year:  2015        PMID: 26248239     DOI: 10.1590/1806-9282.61.03.203

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

1.  Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.

Authors:  Wei Li; Xue Yang; Yuan Deng; Yina Jiang; Guiping Xu; Enxiao Li; Yinying Wu; Juan Ren; Zhenhua Ma; Shunbin Dong; Liang Han; Qingyong Ma; Zheng Wu; Zheng Wang
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.